Gut microbiota have been reported to play an important role in the occurrence and development of malignant tumors.Currently,clinical studies have identified specific gut microbiota and its metabolites associated with ...Gut microbiota have been reported to play an important role in the occurrence and development of malignant tumors.Currently,clinical studies have identified specific gut microbiota and its metabolites associated with efficacy of immunotherapy in multiple types of cancers.Preclinical investigations have elucidated that gut microbiota modulate the antitumor immunity and affect the efficacy of cancer immunotherapy.Certain microbiota and its metabolites may favorably remodel the tumor microenvironment by engaging innate and/or adaptive immune cells.Understanding how the gut microbiome interacts with cancer immunotherapy opens new avenues for improving treatment strategies.Fecal microbial transplants,probiotics,dietary interventions,and other strategies targeting the microbiota have shown promise in preclinical studies to enhance the immunotherapy.Ongoing clinical trials are evaluating these approaches.This review presents the recent advancements in understanding the dynamic interplay among the host immunity,the microbiome,and cancer immunotherapy,as well as strategies for modulating the microbiome,with a view to translating into clinical applications.展开更多
基金supported in part by the National Key Research and Development Program of China(2020YFA0509200)Innovative Research Team of High-Level Local Universities in Shanghai(SSMU-ZLCX20180200)+3 种基金the National Natural Science Foundation of China(82250005,31970718,81830081,81972203)Clinical Research Plan of Shanghai Hospital Development Center(SHDC2020CR1034B)Shanghai Science and Technology Commission(20JC1410100)Shanghai Municipal Health Commission,Collaborative Innovation Cluster Project(2019CXJQ02)。
文摘Gut microbiota have been reported to play an important role in the occurrence and development of malignant tumors.Currently,clinical studies have identified specific gut microbiota and its metabolites associated with efficacy of immunotherapy in multiple types of cancers.Preclinical investigations have elucidated that gut microbiota modulate the antitumor immunity and affect the efficacy of cancer immunotherapy.Certain microbiota and its metabolites may favorably remodel the tumor microenvironment by engaging innate and/or adaptive immune cells.Understanding how the gut microbiome interacts with cancer immunotherapy opens new avenues for improving treatment strategies.Fecal microbial transplants,probiotics,dietary interventions,and other strategies targeting the microbiota have shown promise in preclinical studies to enhance the immunotherapy.Ongoing clinical trials are evaluating these approaches.This review presents the recent advancements in understanding the dynamic interplay among the host immunity,the microbiome,and cancer immunotherapy,as well as strategies for modulating the microbiome,with a view to translating into clinical applications.
